The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans
Open accessAbstract
Here, we describe our collaborative efforts to use N-methyl-d-aspartate (NMDA) receptor antagonists as a translational tool to advance our understanding of the pathophysiology of schizophrenia and identify potential new targets for treatment of schizophrenia. We began these efforts in the late 1980s with a keen sense that, in both human and animal studies, we needed to move beyond the dopamine hypothesis of schizophrenia; if the dopamine hypothesis were correct, the existing dopamine antagonists should have cured the disease but they have not. We used NMDA receptor antagonists, not to produce schizophrenia, but as a tool to provide insights into effects of disturbances in glutamate synaptic function in schizophrenia. Our work has provided insights into potential mechanisms that may contribute to disrupted cortical function in schizophrenia and has helped identify potential treatment targets for the disorder. The translational nature of this study made the clinical testing of the first of these targets feasible. Advances in systems neuroscience approaches in animals and humans make new types of translational research possible; however, our concern is that the current obstacles facing translational research funding and academia-industry collaborations threaten the future progress in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Weakened defences appear to be necessary to activate redoxsensitive neuronal maturation pathways 81 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“NFE2L2 is epigenetically repressed in cortical neurons early in development and what little NFE2L2 exists is highly unstable, leading to reduced intrinsic antioxidant defences 81,83 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“NFE2L2 is only weakly activatable in neurons 81,83”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“Preclinical studies have shown that disinhibition of pyramidal cells through low (subanesthetic) doses of ketamine, an NMDAR antagonist that acts preferentially on PV+ interneurons reducing the excitatory drive onto these cells 130 , normalizes inhibitory connectivity, prevents the silencing of cortical circuits, and extends the lifespan of Mecp2 mutants 131 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [130]
In the citing paper
“Indeed, they express little nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2), a transcription factor and master regulator of antioxidant defence genes 81,82 (Figure 5).”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Self-citationBremner, J. D., Randall, P., Vermetten, E., Staib, L., Bronen, R. A., Mazure, C., Capelli, S., McCarthy, G., Innis, R. B., & Charney, D. S. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00162-x · Cited by 1,283
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Self-citationPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Self-citationStudy of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
AGHAJANIAN, G. K. (1978) · Nature · doi:10.1038/276186a0 · Cited by 802
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Research works printed but not linked: 5
- 1959, JAMA, 81, 363
- Javitt, 1987, The Hillside journal of clinical psychiatry, 9, 12
- 1990, Journal of Neuroscience, 54, 1755
- 1999, Journal of Pharmacology and Experimental Therapeutics, 291, 161
- 2003, 40, 881
Cited by
Zebrafish as an emerging model for studying complex brain disorders
Kalueff, A. V., Stewart, A. M., & Gerlai, R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.002 · Cited by 1,182
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
“A new focus on glutamatergic signaling mediated by NMDA and metabotropic receptors may benefit new drug developments [review by Field et al. (156); Javitt (139); Matosin and Newell (157); Moghadam and Krystal (158); Noetzel et al. (159)].”
BackgroundGlutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
“The existence of binding sites for ketamine and PCP were described in 1979 followed by reports in the early 1980s that they are noncompetitive antagonists of the NMDA subtype of glutamate receptor.(33) Based on clinical observations of patients intoxicated with PCP and ketamine and careful laboratory studies of the ef…”
BackgroundAuditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4002 · Cited by 367
Developmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Metadata
- Authors
- Moghaddam, B., & Krystal, J. H.
- Affiliations
- University of Pittsburgh (US)
- Yale University (US)
- Corresponding author
- Moghaddam, B.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-16
- Volume
- 38
- Issue
- 5
- Pages
- 942-949
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC3446228
- OpenAlex
- W2112492148
- Cited by
- 238
- References
- 54
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 13 · 2021: 16 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 23 · 2016: 24 · 2015: 28 · 2014: 29 · 2013: 11 · 2012: 1
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- NMDA receptor antagonists, schizophrenia
- MeSH terms
- Allosteric Regulation, Animals, Cerebral Cortex, Disease Models, Animal, Dopamine, Emotions, Humans, Ketamine, Neurosciences, Brief Psychiatric Rating Scale, Phencyclidine, Psychoses, Substance-Induced, Schizophrenia, Synapses, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2, Receptors, Metabotropic Glutamate, Glutamic Acid, Translational Research, Biomedical, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans. https://app.cochat.ai/papers/10.1093/schbul/sbs075
- The paper
- Moghaddam, B., & Krystal, J. H. (2012). Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbs075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.